Apricot Capital
VC Fund
Shanghai, China
Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics. Founded in 2015, Apricot Capital consists of more than 20 professionals and consultants with experience in the healthcare industry. Its professional background includes life sciences, medicine, finance and law.
- Total investments:
- 47
- Last investment:
- Lead investor:
- 49%
- Fund size:
- $41M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Apricot Capital invests in
Stages Apricot Capital invests in
Countries Apricot Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $10M–$41M
- Series A
- $3M–$54M
- Series B
- $14M–$90M
Investment Focus
Industry
- Health Care 20 (43%)
- Biotechnology 18 (38%)
- Medical 16 (34%)
- Manufacturing 9 (19%)
- Medical Device 7 (15%)
Stage
- Series A 11 (23%)
- Seed 10 (21%)
- Series B 7 (15%)
- Series C 5 (11%)
- Venture - Series Unknown 3 (6%)
Country
- China 31 (66%)
- United States 4 (9%)
- Hong Kong 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Arthur Qiang
Managing Partner
|
Managing Partner | Total investments: 1 | Find email | |
|
Haigang Chen
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
|
Liu Wenyi
Co-Founding Partner
|
Co-Founding Partner | Total investments: 2 | Find email | |
|
Weixiong Mao
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
Zhen Zhang
Managing Director
|
Managing Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Zhiran Medical
|
Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology. | $89.6M / Series B / Sep 21, 2026 | |
| iRegene researches and develops pharmaceutical therapy for neurodegenerative and rare diseases. | $31M / Series C / Jun 01, 2026 | ||
Microtide Biotechnology
|
Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine. | $7.3M / Series A / Apr 29, 2026 | |
|
Vivatides Therapeutics
|
Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research. | $54M / Series A / Apr 10, 2026 | |
|
Excalipoint Therapetics
|
Excalipoint Therapeutics is a Private limited company. | $27.7M / Seed / Mar 18, 2026 | |
| QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases. | $72.8M / Series C / Mar 02, 2026 | ||
|
Zhiran Medical
|
Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology. | $43.4M / Series A / Feb 11, 2026 | |
|
Microtide Biotechnology
|
Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine. | $22.5M / Series A / Feb 02, 2026 | |
| XinjingZhiyuan is an immune cell therapy company focusing on solid tumors. | $28.7M / Series B / Jan 26, 2026 | ||
Vibrant
|
Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects tocontinuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China. | $61M / Jan 12, 2026 | |
| See all 47 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Apricot Capital invest in?
Apricot Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 47 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Apricot Capital invest in?
Apricot Capital typically joins rounds of $10M–$41M at Seed, $3M–$54M at Series A and $14M–$90M at Series B. These are whole funding-round sizes, not Apricot Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Apricot Capital took part in.
How do I contact Apricot Capital?
Public channels for Apricot Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Apricot Capital?
The team at Apricot Capital includes Arthur Qiang (Managing Partner), Haigang Chen (Managing Partner) and Liu Wenyi (Co-Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
